Peripheral biomarkers' panel for severe COVID-19 patients.
作者信息
d'Alessandro Miriana, Bergantini Laura, Cameli Paolo, Curatola Giuseppe, Remediani Lorenzo, Sestini Piersante, Bargagli Elena
机构信息
Department of Medical and Surgical Sciences and Neurosciences, Respiratory Diseases and Lung Transplantation, Siena University Hospital, Siena, Italy.
出版信息
J Med Virol. 2021 Mar;93(3):1230-1232. doi: 10.1002/jmv.26577. Epub 2020 Oct 10.
Abstract
摘要
相似文献
1
Peripheral biomarkers' panel for severe COVID-19 patients.
J Med Virol. 2021 Mar;93(3):1230-1232. doi: 10.1002/jmv.26577. Epub 2020 Oct 10.
2
Two novel nomograms based on inflammatory cytokines or lymphocyte subsets to differentially diagnose severe or critical and Non-Severe COVID-19.
Aging (Albany NY). 2021 Jul 19;13(14):17961-17977. doi: 10.18632/aging.203307.
3
Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19.
BMC Infect Dis. 2021 Jan 18;21(1):79. doi: 10.1186/s12879-021-05792-7.
4
The predictive role of lymphocyte subsets and laboratory measurements in COVID-19 disease: a retrospective study.
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049739. doi: 10.1177/17534666211049739.
5
Changes of peripheral lymphocyte subset in patients with SARS-CoV-2 infection during the whole course of disease.
Expert Rev Respir Med. 2021 Apr;15(4):553-559. doi: 10.1080/17476348.2021.1866991. Epub 2020 Dec 31.
6
Circulating cell-free DNA, peripheral lymphocyte subsets alterations and neutrophil lymphocyte ratio in assessment of COVID-19 severity.
Innate Immun. 2021 Apr;27(3):240-250. doi: 10.1177/1753425921995577. Epub 2021 Mar 1.
7
Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis.
Iran Biomed J. 2021 Nov 1;25(6):381-9. doi: 10.52547/ibj.25.6.381.
8
Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.
J Med Virol. 2020 Nov;92(11):2600-2606. doi: 10.1002/jmv.26070. Epub 2020 Jun 9.
9
Presepsin as a predictive biomarker of severity in COVID-19: A case series.
J Med Virol. 2021 Jan;93(1):99-101. doi: 10.1002/jmv.26164. Epub 2020 Jun 24.
10
The value of clinical parameters in predicting the severity of COVID-19.
J Med Virol. 2020 Oct;92(10):2188-2192. doi: 10.1002/jmv.26031. Epub 2020 Jun 2.
引用本文的文献
1
The Role of SARS-CoV-2 Nucleocapsidic Antigen and Krebs von den Lungen 6 Serum Levels in Predicting COVID-19 Pneumonia Outcome.
Diagnostics (Basel). 2024 Mar 18;14(6):642. doi: 10.3390/diagnostics14060642.
2
Krebs von den Lungen 6 (KL-6) levels in COVID-19 ICU patients are associated with mortality.
J Anesth Analg Crit Care. 2022 Aug 20;2(1):37. doi: 10.1186/s44158-022-00064-5.
3
MR-proADM as Prognostic Factor of Outcome in COVID-19 Patients.
Biomedicines. 2023 Jun 9;11(6):1680. doi: 10.3390/biomedicines11061680.
4
Serum KL-6 levels predict clinical outcomes and are associated with polymorphism in Japanese patients with COVID-19.
BMJ Open Respir Res. 2023 May;10(1). doi: 10.1136/bmjresp-2023-001625.
5
Autophagy in Inflammatory Response against SARS-CoV-2.
Int J Mol Sci. 2023 Mar 3;24(5):4928. doi: 10.3390/ijms24054928.
6
Transcriptomics secondary analysis of severe human infection with SARS-CoV-2 identifies gene expression changes and predicts three transcriptional biomarkers in leukocytes.
Comput Struct Biotechnol J. 2023;21:1403-1413. doi: 10.1016/j.csbj.2023.02.003. Epub 2023 Feb 9.
7
Exploring the Role of Krebs von den Lungen-6 in Severe to Critical COVID-19 Patients.
Life (Basel). 2022 Jul 28;12(8):1141. doi: 10.3390/life12081141.
8
Clinical Utility of Circulating Pneumoproteins as Diagnostic and Prognostic Biomarkers in COVID-19: A Systematic Review and Meta-analysis.
Infect Dis Ther. 2022 Oct;11(5):1981-1998. doi: 10.1007/s40121-022-00686-w. Epub 2022 Aug 25.
9
Immunosenescence and COVID-19.
Mech Ageing Dev. 2022 Jun;204:111672. doi: 10.1016/j.mad.2022.111672. Epub 2022 Apr 1.
10
Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review.
Front Pharmacol. 2022 Mar 4;13:748931. doi: 10.3389/fphar.2022.748931. eCollection 2022.
本文引用的文献
1
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes.
J Med Virol. 2021 Feb;93(2):657. doi: 10.1002/jmv.26431. Epub 2020 Aug 25.
2
Clinical and radiological diagnosis of non-SARS-CoV-2 viruses in the era of COVID-19 pandemic.
J Med Virol. 2021 Feb;93(2):1119-1125. doi: 10.1002/jmv.26410. Epub 2020 Oct 30.
3
Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID-19 patients.
J Med Virol. 2021 Feb;93(2):786-793. doi: 10.1002/jmv.26300. Epub 2020 Jul 22.
4
Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
Biomark Med. 2020 Jun;14(8):665-674. doi: 10.2217/bmm-2019-0545. Epub 2020 Jul 2.
5
Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study.
Infect Dis (Lond). 2020 Sep;52(9):675-677. doi: 10.1080/23744235.2020.1778178. Epub 2020 Jun 16.
6
Serum KL-6 concentrations as a novel biomarker of severe COVID-19.
J Med Virol. 2020 Oct;92(10):2216-2220. doi: 10.1002/jmv.26087. Epub 2020 Jun 9.
7
Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study.
Infect Dis (Lond). 2020 Jul;52(7):498-505. doi: 10.1080/23744235.2020.1759817. Epub 2020 May 6.
Zotero 插件